<DOC>
	<DOCNO>NCT00024414</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DHA-paclitaxel treating patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>DHA-Paclitaxel Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective tumor response rate prostate-specific antigen response , duration response , time disease progression patient metastatic hormone-refractory prostate cancer treat DHA-paclitaxel . - Determine overall survival patient treated drug . - Determine toxicity profile drug patient . - Assess quality life patient treated drug . OUTLINE : This multicenter study . Patients receive DHA-paclitaxel IV 2 hour day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Quality life assess baseline , every 2 course , study . Patients follow every 3 month . PROJECTED ACCRUAL : A total 18-50 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma prostate Progressive metastatic disease continuous hormonal therapy ( e.g. , orchiectomy luteinizing hormonereleasing hormone ( LHRH ) agonist ) Progressive disease define follow : Measurable disease lesion bone scan Increases prostatespecific antigen ( PSA ) level least 2 consecutive measurement Continued PSA elevation cessation prior antiandrogen therapy ( 4 week flutamide nilutamide 8 week bicalutamide ) PSA level least 5 ng/mL Serum testosterone level le 50 ng/mL Patients undergone prior surgical castration continue primary androgen suppression ( LHRH agonist ) No known clinical evidence CNS metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No uncontrolled ventricular arrhythmia No myocardial infarction within past 3 month No superior vena cava syndrome Neurologic : No peripheral neuropathy great grade 1 No uncontrolled major seizure disorder No spinal cord compression Other : No psychiatric disorder would preclude informed consent No unstable serious concurrent medical condition No concurrent serious infection require parenteral therapy No prior concurrent malignancy except : Curatively treat nonmelanoma skin cancer OR Other cancer curatively treat surgery alone recur 5 year Fertile patient must use effective contraception least 6 month study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior taxanes Prior mitoxantrone prednisone metastatic disease allow At least 28 day since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : See Disease Characteristics No concurrent hormonal therapy Radiotherapy : No prior samarium SM 153 lexidronam pentasodium strontium chloride Sr 89 Prior external radiotherapy metastatic disease allow At least 28 day since prior largefield radiotherapy recover No concurrent radiotherapy , include wholebrain radiotherapy document CNS metastasis Surgery : See Disease Characteristics At least 14 day since prior major surgery recover Other : No prior nonhormonal treatment metastatic disease At least 28 day since prior herbal preparation ( e.g. , PCSPES ) recover No concurrent anticancer medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>